Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 693.85% | 742.51% | 242.98% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 693.85% | 742.51% | 242.98% | -- | -- |
| Cost of Revenue | -17.12% | 33.11% | 36.68% | -- | -- |
| Gross Profit | 51.33% | 155.85% | 18.21% | -- | -- |
| SG&A Expenses | 13.55% | 5.82% | 22.44% | 38.70% | 1.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.23% | 23.02% | 31.82% | 1.46% | -15.32% |
| Operating Income | 13.16% | 86.97% | 2.10% | 16.25% | 24.83% |
| Income Before Tax | 179.13% | -16.17% | -13.78% | 22.89% | 25.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 179.13% | -16.17% | -13.78% | 22.89% | 25.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 179.13% | -16.17% | -13.78% | 22.89% | 25.84% |
| EBIT | 13.16% | 86.97% | 2.10% | 16.25% | 24.83% |
| EBITDA | 13.13% | 88.98% | 1.71% | 17.04% | 25.04% |
| EPS Basic | 133.73% | -42.25% | 3.51% | 71.19% | 68.40% |
| Normalized Basic EPS | 133.73% | -41.83% | 3.30% | 69.51% | 68.40% |
| EPS Diluted | 133.73% | -42.25% | 3.51% | 71.19% | 68.40% |
| Normalized Diluted EPS | 133.73% | -41.83% | 3.30% | 69.51% | 68.40% |
| Average Basic Shares Outstanding | 134.57% | -18.33% | 17.92% | 167.61% | 134.69% |
| Average Diluted Shares Outstanding | 134.57% | -18.33% | 17.92% | 167.61% | 134.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |